Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
EBITDA history
Currency unavailable · from the income statement
No EBITDA data reported for this period type.
EBITDA vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.55M USD | -66.6% | — | 7.6% | |
| LTM Mar 2026 | $3.16M USD | -81.4% | +17.2% | 2.7% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | -SEK 248.71M SEK | -24.2% | — | 18700.4% |
| LTM Jun 2026 | -$770.76M USD | +17.8% | — | 67.8% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding AVLN) | — | -45.4% | +17.2% | 37.7% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.